China’s Mabworks Biotech Raises US$160M in Two Series C Rounds
The company develops therapeutic antibodies via integrated technology. Beijing-based biotech and pharmaceutical company Beijing Mabworks Biotech announced that it had raising funding up to RMB 1.13 billion (US $160 million) in its Series C1 and C2, DealStreetAsia reported today. The capital will be used to strengthen Mabworks’ research and development efforts, and commercialize its macromolecule […]
China’s Mabworks Biotech Raises US$160M in Two Series C Rounds Read More »
The company develops therapeutic antibodies via integrated technology. Beijing-based biotech and pharmaceutical company Beijing Mabworks Biotech announced that it had raising funding up to RMB 1.13 billion (US $160 million) in its Series C1 and C2, DealStreetAsia reported today. The capital will be used to strengthen Mabworks’ research and development efforts, and commercialize its macromolecule










